Build a KOL Community Virtually – Engaging Your Advisors Creatively
October 9, 2025 | Community board, HCP Discussion, HCP engagement, HCP forum, Impetus Digital, KOL community board, KOL virtual community, MCL relationships, Pharma community, Pharma tips, Pharma trends, Virtual Engagement, advisor engagement, discussion forum, life science community, peer to peer sharing, virtual advisor
Go beyond formal meetings! Discover a creative way to build a virtual KOL community through ongoing discussion forums. Facilitate peer-to-peer best practice sharing and foster authentic, sustained relationships with your advisors.
Discover how to sustain engagement and build long-term relationships with your advisors. Explore the power of ongoing HCP discussion forums as a supplement to formal advisory touchpoints. Learn how keeping a dialogue forum open for peer-to-peer best practice sharing helps your advisors feel part of a valuable community of KOLs, fostering authentic relationships and continuous engagement.
- Ongoing HCP Discussion Forums
- Use open forums to facilitate peer-to-peer best practice-sharing among advisors.
- Help advisors feel like part of a long-term community and build authentic relationships.
- Facilitate ongoing communication between various stakeholders (e.g., MSLs and clinicians).
- Understand how this approach supplements, but does not replace, formal touchpoints.
For more creative ways to engage your advisors, visit: https://www.impetusdigital.com/2019/11/15/top-10-creative-ways-to-engage-your-advisors/
Learn more about Impetus Digital’s solutions: www.impetusdigital.com
Schedule a consultation: https://meetwithimpetus.com/
Stay connected:
- LinkedIn: https://linkedin.com/company/impetus-digital
- Twitter: https://twitter.com/impetus_digital
- Facebook: https://facebook.com/ImpetusDigital.fb
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Clinical Trial Protocol Conceptualization: A Customer Story
To set their Phase II clinical trial of a novel anti-cancer compound up for success, our client sought early multidisciplinary insights on current unmet needs, as well as feedback on their preclinical…
Mastering Asynchronous Meetings: Open-Ended Questions – Impetus Digital Tip 1
Unlock the potential of asynchronous virtual meetings with the first tip from our “Top 10 Tips for Optimizing Asynchronous Virtual Meetings”.
In-person, hybrid, or digital? State of Pharma meetings and events in 2024
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.
Navigating Regulatory Challenges – Top 10 Most Important Advisor Questions
This quick video covers #9 of our Top 10 Most Important Advisor Questions, shedding light on the complexities of local and national regulatory issues in the Pharma and Life Sciences…
Top-5 Trends in Virtual KOL Engagement
Register now for one of our upcoming webinars (February 26-28)
Engaging with Different Perspectives – Top 10 Most Important Advisor Questions
In this quick clip, we highlight a vital tip from our ‘Top 10 Most Important Advisor Questions’ – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences….
Patient Advocate Engagement: A Customer Story
Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient…
Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions
In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today’s diverse healthcare landscape. 7….
Trends in Virtual Collaboration
Join us for a look at the top-5 emerging virtual collaboration trends…
Advisor Questions on Potential Data or Knowledge Gaps
As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here’s another one to keep in…